Raleigh, N.C., Dec. 6, 2012 – INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Robert Ryan, PhD, as Vice President, Regulatory Strategy, Consulting and Submissions. Dr. Ryan will provide global leadership to position INC Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings. In this role he will continue to build on the Company’s strong reputation in helping biopharmaceutical customers worldwide navigate through the complexities of the regulatory environment to accelerate their time to market.
“Robert brings a unique blend of strategic leadership skills and international regulatory expertise that speaks to biopharmaceutical companies looking for guidance along the entire continuum of the drug development lifecycle,” said Tim Dietlin, Senior Vice President, Global Consulting and Strategic Alliances. “Our Regulatory Consulting and Submissions team has a long history of exceptional work, and we look forward to continuing this track record under Robert’s leadership.”
Dr. Ryan is an experienced senior regulatory affairs executive with more than two decades of experience in the biopharmaceutical industry. He brings a unique blend of scientific and business acumen to the position, having held regulatory and executive leadership positions in both the CRO and biopharmaceutical industries with companies such as Quintiles, PPD, Celtic Therapeutics and Schwarz Pharma. Most recently, he was Chairman of the Board for Levare, LLC, a CNS/pain pharmaceutical development company. Dr. Ryan has been directly involved in the approval of more than 20 drugs throughout his career. He holds a doctorate in toxicology from the University of North Carolina at Chapel Hill, master’s degrees in pharmacokinetics and genetics. Dr. Ryan is a diplomate of the American Board of Toxicology.
With a network of global locations and on-the-ground expertise in all key markets, INC Research is committed to delivering superior quality regulatory services to help customers design the most efficient product development programs. The Company supports customer needs across the entire product lifecycle, from early regulatory development strategy consultations to clinical trial and marketing authorization submissions and post-licensing support. INC Research’s service portfolio ranges from new chemical entities (NCEs) to biologics, biosimilars, well-established substances 505(b)(2) pathway, generic drugs, devices and in vitro diagnostics. With in-house expertise in drug-device combination products and medical devices, the Company also is able to offer a range of strategic and operational services, including clinical investigation submissions and CE-marking (Conformité Européenne) expertise. For more information on INC Research’s Regulatory Consulting and Submissions services, please visit the online Resource Library.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women’s health trials. The company’s Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
